267 reports of this reaction
6.3% of all DIHYDROERGOTAMINE MESYLATE reports
#4 most reported adverse reaction
HYPERHIDROSIS is the #4 most commonly reported adverse reaction for DIHYDROERGOTAMINE MESYLATE, manufactured by Impel Pharmaceuticals LLC. There are 267 FDA adverse event reports linking DIHYDROERGOTAMINE MESYLATE to HYPERHIDROSIS. This represents approximately 6.3% of all 4,245 adverse event reports for this drug.
Patients taking DIHYDROERGOTAMINE MESYLATE who experience hyperhidrosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPERHIDROSIS is moderately reported among DIHYDROERGOTAMINE MESYLATE users, representing a notable but not dominant share of adverse events.
In addition to hyperhidrosis, the following adverse reactions have been reported for DIHYDROERGOTAMINE MESYLATE:
The following drugs have also been linked to hyperhidrosis in FDA adverse event reports:
HYPERHIDROSIS has been reported as an adverse event in 267 FDA reports for DIHYDROERGOTAMINE MESYLATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPERHIDROSIS accounts for approximately 6.3% of all adverse event reports for DIHYDROERGOTAMINE MESYLATE, making it a notable side effect.
If you experience hyperhidrosis while taking DIHYDROERGOTAMINE MESYLATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.